Search Result

Results for "

Histone Methyltransferase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	DNA Methyltransferase (4) HDAC (4) Histone Acetyltransferase (1) Histone Demethylase (4) Histone Methyltransferase (98) Akt (1) Aldehyde Dehydrogenase (ALDH) (1) Antibiotic (1) Apoptosis (21) Autophagy (7) Bacterial (1) Biochemical Assay Reagents (1) c-Myc (1) Caspase (1) CD44 (1) Chemerin Receptor (1) Cholinesterase (ChE) (1) Discoidin Domain Receptor (1) DNA/RNA Synthesis (1) Drug Metabolite (1) Epigenetic Reader Domain (2) Fungal (1) GCGR (1) Histamine Receptor (1) HOXA (1) Influenza Virus (2) Interleukin Related (1) Keap1-Nrf2 (1) MDM-2/p53 (1) NF-κB (1) Orthopoxvirus (4) Parasite (2) PKC (1) Potassium Channel (1) Reference Standards (6) S-adenosylhomocysteine hydrolase (SAHH) (3) SARS-CoV (1) Sirtuin (2) TNF Receptor (1) VSV (2) WDR5 (9)
By Research Areas:	Cancer (101) Cardiovascular Disease (5) Infection (11) Inflammation/Immunology (9) Metabolic Disease (3) Neurological Disease (3)
Click Chemistry:	Alkynes (1)

113

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Click Chemistry

GMP Molecules

Targets Recommended: Histone Methyltransferase Histone Demethylase HDAC Amine N-methyltransferase Histone Acetyltransferase METTL3 COMT ICMT RNA MTase DNA Methyltransferase

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-15593

Pinometostat 25+ Cited Publications EPZ-5676	Histone Methyltransferase	Cancer
Pinometostat (EPZ-5676) is a potent DOT1L histone methyltransferase inhibitor with a K_i of 80 pM.

HY-10442

3-Deazaneplanocin A Maximum Cited Publications 35 Publications Verification DZNep; 3-Deazaneplanocin	Histone Methyltransferase S-adenosylhomocysteine hydrolase (SAHH) Orthopoxvirus	Infection Metabolic Disease Inflammation/Immunology Cancer
3-Deazaneplanocin A (DZNep) is a potent histone methyltransferase EZH2 inhibitor . 3-Deazaneplanocin A is a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor. 3-Deazaneplanocin A shows anti-orthopoxvirus activity .

HY-136328

EZM0414 TFA 5+ Cited Publications SETD2-IN-1 TFA	Histone Methyltransferase	Cancer
EZM0414 (SETD2-IN-1) TFA is the TFA salt form of EZM0414 (HY-144858). EZM0414 TFA is a potent, selective, orally active inhibitor of SETD2 (IC₅₀=18 nM in SETD2 biochemical assay; IC₅₀=34 nM in cellular assay). EZM0414 TFA can be used for the research of relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma .

HY-153390

AMG-193	Histone Methyltransferase	Cancer
AMG 193 is an orally active MTA-cooperative PRMT5 inhibitor with antitumor activity. AMG 193, when complexed with MTA, preferentially inhibits the growth of MTAP-deficient tumor cells by inhibiting PRMT5 (IC₅₀=0.107 μM), thereby protecting normal cells with wild-type MTAP .

HY-154812

Gintemetostat KTX-1001	Histone Methyltransferase CD44	Cancer
Gintemetostat (KTX-1001) is an orally active, highly specific NSD2/MMSET histone methyltransferase inhibitor with human NSD2 IC₅₀ values ranging 0.460-2.17 nM and NSD2 SET domain IC₅₀ of 2.32 nM and K_d values ranging 6.3-70.4 nM .Gintemetostat reduces H₃K₃₆me₂ levels, impairs multiple myeloma cell adhesion and colony formation, enhances cytotoxicity, boosts T-cell activation, and sensitizes resistant multiple myeloma cells to other agents .Gintemetostat can be used for the research of multiple myeloma and relapsed and refractory multiple myeloma .

HY-112445

SGC3027 5+ Cited Publications	Histone Methyltransferase	Cancer
SGC3027 is a **histone methyltransferase inhibitor . SGC3027 is the first potent, selective and cell active chemical probe for PRMT7** .

HY-N2019

Chaetocin 5+ Cited Publications	Histone Methyltransferase Bacterial Antibiotic	Infection Cancer
Chaetocin is a specific inhibitor of the histone methyltransferase (HMT) SU(VAR)3-9 with an IC₅₀ of 0.6 μM for SU(VAR)3-9. It also inhibits thioredoxin reductase (TrxR) with an IC₅₀ of 4 μM.

HY-12186

3-Deazaneplanocin A hydrochloride Maximum Cited Publications 35 Publications Verification DZNep hydrochloride; NSC 617989 hydrochloride; 3-Deazaneplanocin hydrochloride	Histone Methyltransferase S-adenosylhomocysteine hydrolase (SAHH) Orthopoxvirus	Infection Inflammation/Immunology Cancer
3-Deazaneplanocin A hydrochloride (DZNep hydrochloride) is a potent histone methyltransferase EZH2 inhibitor . 3-Deazaneplanocin A hydrochlorideis a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor . 3-Deazaneplanocin A hydrochloride also has anti-orthopoxvirus and anti-variola activities .

HY-100201

A-196 10+ Cited Publications	Histone Methyltransferase	Cancer
A-196 is a potent and selective inhibitor of SUV420H1 and SUV420H2 with IC₅₀ values of 25 nM and 144 nM, respectively. A-196 inhibits SUV4-20 biochemically in a substrate-competitive manner. A-196 represents a first-in-class chemical probe of SUV4-20 to investigate the role of histone methyltransferases in genomic integrity .

HY-12583

A-366 5+ Cited Publications	Histone Methyltransferase Epigenetic Reader Domain	Cancer
A-366, a chemical probe, is a potent, highly selective, peptide-competitive histone methyltransferase G9a inhibitor with IC₅₀s of 3.3 and 38 nM for G9a and GLP (EHMT1), respectively. A-366 shows >1000-fold selectivity over 21 other methyltransferases. A-366 is also a potent, nanomolar inhibitor of the Spindlin1-H3K4me3-interaction (IC₅₀=182.6 nM). A-366 displays high affinity at human histamine H3 receptor (K_i=17 nM) and shows subtype selectivity among subsets of the histaminergic and dopaminergic receptor families .

HY-15273

UNC0638 10+ Cited Publications	VSV Histone Methyltransferase Autophagy Influenza Virus	Infection Cancer
UNC0638, a chemical probe, selectively inhibits G9a and GLP histone methyltransferases with IC₅₀ of 15 nM and 19 nM, respectively. UNC0638 inhibits TNBC cell invasion and migration in vitro. UNC0638 is also an inhibitor of EHMT1/2 and induces fetal hemoglobin (HbF) expression in human erythroid progenitor cell culture. In addition, UNC0638 has anti-FMDV (foot-and-mouth disease virus) and anti-VSV (vesicular stomatitis virus) activities, with excellent potency and selectivity against multiple epigenetic and non-epigenetic targets .

HY-12220

MM-102 4 Publications Verification HMTase Inhibitor IX	WDR5 Apoptosis NF-κB TNF Receptor Interleukin Related	Inflammation/Immunology Cancer
MM-102 (HMTase Inhibitor IX) is a cell-permeable and tightly binding inhibitor of MLL1-WDR5 interaction (IC₅₀=2.4 nM). MM-102 can specifically inhibit the growth and induce apoptosis of leukemia cells containing MLL1 fusion protein, and reduce renal fibrosis and inflammation in mice with ischemia-reperfusion injury. In addition, MM-102 also acts as an H3K4 histone methyltransferase inhibitor to improve the development of porcine somatic cell nuclear transfer (SCNT) embryos .

HY-13808

UNC 0631 5 Publications Verification	Histone Methyltransferase	Cancer
UNC 0631 is a potent histone methyltransferase G9a inhibitor with an IC₅₀ of 4 nM. UNC 0631 potently reduces H3K9me2 levels in MDA-MB-231 cells with an IC₅₀ of 25 nM .

HY-16705

BRD4770 5 Publications Verification	Histone Methyltransferase	Cancer
BRD4770 is a histone methyltransferase G9a inhibitor. BRD4770 reduces di- and trimethylation of *lysine 9 on histone* H3 (H3K9) with an EC₅₀** of 5 μM, and has less or little effect toward H3K27me3, H3K36me3, H3K4me3, and H3K79me3. BRD4770 can activate the ataxia telangiectasia mutated (ATM) pathway and induce cell senescence .

HY-10929

UNC0224 2 Publications Verification	Histone Methyltransferase	Cancer
UNC0224 is a potent and selective histone methyltransferase G9a inhibitor with a K_i of 2.6 nM, an IC₅₀ of 15 nM and a K_d of 23 nM. UNC0224 also potently inhibits b>GLP with assay-dependent IC₅₀ values of 20-58 nM. UNC0224 is inactive against SET7/9, SET8/PreSET7, PRMT3 and JMJD2E .

HY-10930

UNC0321 2 Publications Verification	Histone Methyltransferase GCGR Apoptosis	Cancer
UNC0321 is a potent and selective histone methyltransferase G9a inhibitor with a K_i of 63 pM and with assay-dependent IC₅₀ values of 6-9 nM. UNC0321 also inhibits GLP with assay-dependent IC₅₀ values of 15-23 nM. UNC0321 has anti-apoptotic activity and has potential application in diabetic vascular complications .

HY-141429A

AS-99 TFA 2 Publications Verification	Histone Methyltransferase Apoptosis	Cancer
AS-99 TFA is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC₅₀= 0.79 μM, K_d= 0.89 μM) with anti-leukemic activity. AS-99 TFA blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .

HY-141539

SETDB1-TTD-IN-1 5 Publications Verification	Histone Methyltransferase Akt	Cancer
SETDB1-TTD-IN-1 is a SETDB1 methyltransferase activator and SETDB1-TTD competitive inhibitor (K_d of 88 nM), and selectivity for SETDB1-TTD over other tudor and bromodomain proteins. SETDB1-TTD-IN-1 stimulates methyltransferase activity via increased catalytic activity, promotes Akt1 Lys64 methylation, Akt1 Thr308 phosphorylation and activation. SETDB1-TTD-IN-1 prevents SETDB1-TTD-histone H3 peptide association, induces global gene expression changes, exhibits cellular target engagement, and acts as a tool compound for SETDB1-TTD function exploration. SETDB1-TTD-IN-1 can be used for the research of breast cancer .

HY-148458

EZH2-IN-14	Histone Methyltransferase	Cancer
EZH2-IN-14 is a selective EZH2 (Histone *Methyltransferase) inhibitor with an IC₅₀* of 12 nM. EZH2-IN-14 inhibits the methyltransferase activity of EZH2/PRC2 (that is, reducing H3K27me3). EZH2-IN-14 shows >200-fold selective for EZH2 over the highly homologous H3K27 methyltransferase EZH1 .

HY-15647

BRD9539 1 Publications Verification	Histone Methyltransferase	Cancer
BRD9539 is a histone methyltransferase G9a inhibitor with an IC₅₀ of 6.3 μM. BRD9539 also inhibits PRC2 activity and is inactive against SUV39H1, NSD2 and DNMT1 .

HY-13807

UNC0646 1 Publications Verification	Histone Methyltransferase	Cancer
UNC0646 is a potent and selective histone methyltransferase G9a inhibitor with an IC₅₀ of 6 nM. UNC0646 is also a potent GLP inhibitor (IC₅₀ <15 nM) and highly selective for G9a/GLP over SETD7, SUV39H2, SETD8 and PRMT3. UNC0646 reduces H3K9me2 levels in MDA-MB-231 cells with an IC₅₀ of 26 nM .

HY-122182

OTS193320	Histone Methyltransferase Apoptosis	Cancer
OTS193320, a imidazo[1,2-a]pyridine compound, is a SUV39H2 methyltransferase activity inhibitor. OTS193320 decreases global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggers apoptotic cell death. Combination of OTS193320 with Doxorubicin (HY-15142A) results in reduction of γ-H2AX levels as well as cancer cell viability compared to a single agent OTS193320 or DOX .

HY-A0298

EZH2-IN-2	Histone Methyltransferase	Cancer
EZH2-IN-2 (Example 69) is a EZH2 inhibitor with an IC₅₀ and a TR-FRET IC₅₀ of 64 nM and 20 nM. EZH2-IN-2 can be used for the research of cancer or precancerous condition related to EZH2 activity .

HY-135127

Dot1L-IN-4 1 Publications Verification	Histone Methyltransferase	Cancer
Dot1L-IN-4 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC_{50 SPA DOT1L} of 0.11 nM .

HY-13808R

UNC 0631 (Standard)	Reference Standards Histone Methyltransferase	Cancer
UNC 0631 (Standard) is the analytical standard of UNC 0631. This product is intended for research and analytical applications. UNC 0631 is a potent histone methyltransferase G9a inhibitor with an IC₅₀ of 4 nM. UNC 0631 potently reduces H3K9me2 levels in MDA-MB-231 cells with an IC₅₀ of 25 nM .

HY-121093

DC-S239	Histone Methyltransferase	Cancer
DC-S239 is a selective histone methyltransferase SET7 inhibitor with an IC₅₀ value of 4.59 μM. DC-S239 also displays selectivity for DNMT1, DOT1L, EZH2, NSD1, SETD8 and G9a. DC-S239 has anticancer activity .

HY-12310

RSC133	DNA Methyltransferase HDAC MDM-2/p53	Others Inflammation/Immunology
RSC133 is a dual inhibitor of *DNA methyltransferase* 1** and histone deacetylase 1 inhibitor. RSC133 promotes cell proliferation, up-regulates H₃K₉ histone acetylation, down-regulates p53, p21, p16/INK4A, and ablates pro-senescence phenotypes .

HY-12991A

BIX-01338 hydrate	Histone Methyltransferase	Cancer
BIX-01338 hydrate is a **histone lysine methyltransferase** inhibitor.

HY-114209

MRK-740 2 Publications Verification	Histone Methyltransferase	Cancer
MRK-740, a chemical probe, is a potent, selective and substrate-competitive PRDM9 histone methyltransferase inhibitor with an IC₅₀ of 80?nM. MRK-740 is more selective for PRDM9 than other histone methyltransferases and other non-epigenetic targets. MRK-740 reduces PRDM9-dependent trimethylation of H3K4 (IC₅₀?=?0.8?μM) .

HY-100757

CPUY074020	Histone Methyltransferase	Cancer
CPUY074020 is a potent and oral bioavailable inhibitor of histone methyltransferase G9a, with an IC₅₀ of 2.18 μM. CPUY074020 possesses anti-proliferative activity .

HY-135128

Dot1L-IN-5 2 Publications Verification	Histone Methyltransferase	Cancer
Dot1L-IN-5 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC₅₀ of 0.17 nM .

HY-133121

WDR5-IN-1	Apoptosis WDR5	Cancer
WDR5-IN-1 is a potent and selective WD repeat domain 5 (WDR5) inhibitor, with a K_d of <0.02 nM. WDR5-IN-1 inhibits MLL1 histone methyltransferase (HMT) activity with an IC₅₀ of 2.2 nM. WDR5-IN-1 diminishes MYC recruitment at WDR5-displaced genes and exhibits potent anti-proliferative effects in CHP-134 (neuroblastoma) and Ramos (Burkitt’s lymphoma) lines .

HY-19554A

MM-401 TFA 1 Publications Verification	WDR5 Apoptosis	Cancer
MM-401 (TFA) is a MLL1 H3K4 methyltransferase inhibitor. MM-401 inhibits MLL1 activity (IC₅₀ = 0.32 μM) by blocking MLL1-WDR5 interaction. MM-401 can induce cell cycle arrest, apoptosis and differentiation. MM-401 can be used for the research of MLL leukemia .

HY-168992

UNC6535	Histone Methyltransferase	Neurological Disease Cancer
UNC6535 is a covalent ligand targeting the SETDB1 triple Tudor domain (3TD) with negative allosteric modulator properties, with an IC₅₀ of 3.4 μM and a K_d of 4.2 μM. UNC6535 inhibits the methyltransferase activity of recombinant SETDB1 protein lacking the 3TD domain. UNC6535 reversibly binds to the aromatic cages of both TD2 and TD3 subdomains of SETDB1 3TD simultaneously, displacing the endogenous H3K9Me2K14Ac histone tail ligand. UNC6535 can be used in research on cancer and neurodegenerative diseases .

HY-141430

AS-85	Histone Methyltransferase	Cancer
AS-85 is a potent ASH1L histone methyltransferase inhibitor (IC₅₀=0.6 μM) with anti-leukemic activity. AS-85 strongly binds to the ASH1L SET domain, with the K_d value of 0.78 μM .

HY-44062

G9a-IN-1	Histone Methyltransferase	Inflammation/Immunology Cancer
G9a-IN-1 (Compound 113) is a G9a protein inhibitor. G9A/EHMT2 is a nuclear histone lysine methyltransferase that catalyzes histone H3 lysine 9 dimethylation (H3K9me2), which is a reversible modification generally associated with transcriptional gene silencing. G9a-IN-1 can be used for the research of autoimmune disorders or cancer .

HY-P10948A

CS-VIP 8 hydrochloride	WDR5 Histone Methyltransferase	Cardiovascular Disease
CS-VIP 8 hydrochloride is a selective allosteric WDR5 protein inhibitor (K_i= 0.008 μM). CS-VIP 8 hydrochloride induces conformational changes in the MLL1 complex, leading to the dissociation of MLL1 from the complex, inhibiting MLL1 histone methyltransferase activity and regulating HOX gene expression. CS-VIP 8 hydrochloride is promising for research of hematological diseases such as leukemia .

HY-153331

DDO-2213	WDR5	Cancer
DDO-2213 is an orally active and potent WDR5-MLL1 inhibitor, with an IC₅₀ of 29 nM and a K_d value of 72.9 nM for the WDR5 protein. DDO-2213 selectively inhibits MLL (mixed lineage leukemia) histone methyltransferase activity and the proliferation of MLL translocation-harboring cells. DDO-2213 can be used for MLL fusion leukemia research .

HY-156285

ZZM-1220	Histone Methyltransferase Apoptosis	Cancer
ZZM-1220 is a histone *lysine methyltransferase* G9a/GLP covalent inhibitor with IC₅₀s of of 458 nM and 924 nM, respectively. ZZM-1220 inhibits H3K9me2 in cells and significantly induces apoptosis** of triple-negative breast cancer (TNBC) cells and blocks the cell cycle in the G2/M phase .

HY-P2254

H3K27(Me3) (15-34)	Histone Methyltransferase	Cancer
H3K27(Me3) (15-34), a histone peptide, is a repressive chromatin mark derived from human histone. Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of H3K27(Me) .

HY-19554

MM-401	WDR5 Apoptosis	Cancer
MM-401 is a MLL1 H3K4 methyltransferase inhibitor. MM-401 inhibits MLL1 activity (IC₅₀ = 0.32 μM) by blocking MLL1-WDR5 interaction. MM-401 can induce cell cycle arrest, apoptosis and differentiation. MM-401 can be used for the research of MLL leukemia .

HY-141429

AS-99 free base 2 Publications Verification	Histone Methyltransferase Apoptosis	Cancer
AS-99 is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC₅₀= 0.79 µM, K_d= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .

HY-148817

WDR5-0102	WDR5	Cancer
WDR5-0102 is an inhibitor of WDR5. WDR5-0102 specifically targets the WIN site of WDR5, disrupts the WDR5-MLL1 interaction, and reduces the histone methyltransferase activity of MLL1. WDR5-0102 exerts dose-dependent toxicity on MDSC-like cells and reduces their osteopontin levels, while showing extremely low cytotoxicity to pancreatic cancer cells. WDR5-0102 can be used in the research of related diseases such as acute myeloid leukemia, lymphoid leukemia, biphenotypic leukemia and pancreatic cancer .

HY-172614

RK-0080552 RK-552	Histone Methyltransferase Apoptosis	Cancer
RK-0080552 (RK-552) is a NSD2 inhibitor with an IC₅₀ of 0.11 μM, and it exhibits selectivity over histone methyltransferases G9a (IC₅₀: 1.2 μM) and SET7/9 (IC₅₀: >50 μM). RK-0080552 functionally inhibits NSD2 histone methyltransferase activity, reduces the dimethylation level of histone H3 lysine 36, suppresses IRF4 transcription, induces apoptosis and triggers cell death. RK-0080552 inhibits the growth of xenograft tumors and prolongs host survival. RK-0080552 is available for the research of multiple myeloma .

HY-125244

LEM-14-1189	Histone Methyltransferase	Cancer
LEM-14-1189, a LEM-14 (HY-114340) derivative, is a NSDs inhibitor with IC₅₀s of 418 μM (NSD1), 111 μM (NSD2), and 60 μM (NSD3), respectively. The NSDs, histone lysine methyltransferases (HMTases), are oncoproteins, drivers of a number of tumors. LEM-14-1189 can be used for multiple myeloma (MM) research .

HY-P10463

ssK36	Histone Methyltransferase	Cancer
ssK36 is a supersubstrate peptide of the histone methyltransferase (SET) domain protein 2 (SETD2), and ssK36 is designed for the SETD2 protein, a specific PKMT. ssK36 is responsible in human cells for adding methyl groups to the 36th lysine residue of histone H3 (H3K36) to form H3K36me3. ssK36 can be methylated by SETD2 at a rate more than 100 times faster than the natural substrate H3K36. ssK36 can be used to study the catalytic mechanism of PKMTs, especially substrate specificity and catalytic efficiency .

HY-W516880

Desmethylastemizole O-Demethylastemizole	Drug Metabolite Parasite Histamine Receptor Potassium Channel	Infection Cardiovascular Disease
Desmethylastemizole (O-Demethylastemizole) , a metabolite of Astemizole (HY-12532), is a β-hematin (βH) inhibitor. Desmethylastemizole has an antiplasmodium activity against P. falciparum with IC₅₀ of 0.12, 0.11 and 0.06  μM for Pf3D7, PfDd2, and PfItG strains, respectively. Desmethylastemizole is also a Histamine H1 receptor antagonist. Desmethylastemizole significantly blocks hERG K ⁺ channels and also inhibits histone-lysine N-methyltransferase EZH2 activity. Desmethylastemizole can be used for long QT syndrome and malaria research .

HY-122936

Tanshindiol C	Histone Methyltransferase Keap1-Nrf2 Sirtuin	Cardiovascular Disease Cancer
Tanshindiol C is a S-adenosylmethionine-competitive EZH2 (Histone *Methyltransferase) inhibitor with an IC₅₀* of 0.55 μM for inhibiting the methyltransferase activity. Tanshindiol C is also an activator of both Nrf2 and Sirtuin 1 (Sirt1) in macrophages. Tanshindiol C possesses anti-cancer activity, and can be used for atherosclerosis research .

HY-P10948

CS-VIP 8	WDR5 Histone Methyltransferase	Cardiovascular Disease
CS-VIP 8 is a selective allosteric WDR5 protein inhibitor (K_i= 0.008 μM). CS-VIP 8 induces conformational changes in the MLL1 complex, leading to the dissociation of MLL1 from the complex, inhibiting MLL1 histone methyltransferase activity and regulating HOX gene expression. CS-VIP 8 is promising for research of hematological diseases such as leukemia .

HY-P10463A

ssK36 TFA	Histone Methyltransferase	Cancer
ssK36 TFA is a supersubstrate peptide of the histone methyltransferase (SET) domain protein 2 (SETD2) , and ssK36 TFA is designed for the SETD2 protein, a specific PKMT. ssK36 TFA is responsible in human cells for adding methyl groups to the 36th lysine residue of histone H3 (H3K36) to form H3K36me3. ssK36 TFA can be methylated by SETD2 at a rate more than 100 times faster than the natural substrate H3K36. ssK36 TFA can be used to study the catalytic mechanism of PKMTs, especially substrate specificity and catalytic efficiency .

Cat. No.	상품명

HY-L024

Histone Modification Research Compound Library

904 compounds

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 904 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

HY-L203

Methylation Compound Library

338 compounds

Methylation is an epigenetic modification mechanism that involves adding methyl groups to molecules such as DNA and histones, which can alter gene expression without changing the DNA sequence. This process is catalyzed by enzymes such as DNA methyltransferases (DNMTs) and histone methyltransferases (HMTs), and can be reversed by demethylases. The balance of methylation and demethylation is crucial for maintaining cellular function and genomic stability. Abnormal regulation of methylation may lead to a variety of diseases, including cancer, neurological disorders, and developmental abnormalities. A deep understanding of the molecular mechanisms of methylation metabolism is essential for developing therapeutic strategies for diseases associated with methylation dysregulation.

MCE contains 338 compounds targeting methylation/demethylation enzymes, which is of significant value for studying the pathways of methylation metabolism and exploring their mechanisms of action in diseases.

HY-L005M

Epigenetics Compound Library Mini

297 compounds

Epigenetics involves heritable phenotypic changes that occur without alterations to the underlying DNA sequence. Key mechanisms include DNA methylation, histone modifications, and regulation by small non-coding RNAs such as microRNAs. By modifying DNA, histones, or RNA—while leaving their primary sequences intact—these processes influence molecular function and regulation, thereby playing critical roles in cellular differentiation, embryonic development, gene expression control, aging, and diseases such as cancer.

MCE provide a unique collection of 297 epigenetics-related compounds. For each regulatory target and its subtype, 3 to 5 highly specific representative compounds have been retained, which can be used in epigenetic and related disease research.

HY-L005

Epigenetics Compound Library

1,945 compounds

Epigenetics refers to changes in phenotype that are not rooted in DNA sequence. Many types of epigenetic processes have been identified, including DNA methylation, alteration in the structure of histone proteins and gene regulation by small noncoding microRNAs. Modification of DNA, protein, or RNA, resulting in changes to the function and/or regulation of these molecules, without altering their primary sequences, reveals the complexities of cellular differentiation, embryology, the regulation of gene expression, aging, cancer, and other diseases.

MCE provide a unique collection of 1,945 epigenetics-related compounds that can be used in the research of the related diseases.

Cat. No.	상품명	Type

HY-12186G

3-Deazaneplanocin A hydrochloride DZNep hydrochloride; NSC 617989 hydrochloride; 3-Deazaneplanocin hydrochloride	Fluorescent Dyes
3-Deazaneplanocin A (DZNep) hydrochloride (GMP) is 3-Deazaneplanocin A hydrochloride (HY-12186) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. 3-Deazaneplanocin A hydrochloride is a potent histone methyltransferase EZH2 inhibitor .

HY-13689G

Go 6983

Fluorescent Dyes

Go 6983 GMP is Go 6983 (HY-13689) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Go 6983 is a dual inhibitor targeting Suv39h1/2 (KMT1A/KMT1B) and PKC, as well as a transcriptional activator capable of inducing DNA hypomethylation. Go 6983 stimulates the transcription of Prdm14 by reducing Suv39h1/2 protein levels, decreasing histone modifications in the Prdm14 promoter region, and increasing the recruitment of RNA polymerase II. Go 6983 induces genome-wide DNA hypomethylation by inhibiting de novo methyltransferase expression and increasing Tet1/Tet2 levels, thereby promoting self-renewal and pluripotency maintenance of stem cells. Meanwhile, Go 6983 can block PKC-mediated signaling pathways to reduce the expression of EMT-related genes and eliminate the upregulation of antioxidant genes downstream of NRF2. Go 6983 is mainly used in mechanism studies related to myocardial ischemia/reperfusion injury .

Cat. No.	상품명	Type

HY-12186G

3-Deazaneplanocin A hydrochloride DZNep hydrochloride; NSC 617989 hydrochloride; 3-Deazaneplanocin hydrochloride	Biochemical Assay Reagents
3-Deazaneplanocin A (DZNep) hydrochloride (GMP) is 3-Deazaneplanocin A hydrochloride (HY-12186) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. 3-Deazaneplanocin A hydrochloride is a potent histone methyltransferase EZH2 inhibitor .

HY-13689G

Go 6983

Biochemical Assay Reagents

Cat. No.	상품명	Target	Research Area

HY-P10948A

CS-VIP 8 hydrochloride	WDR5 Histone Methyltransferase	Cardiovascular Disease
CS-VIP 8 hydrochloride is a selective allosteric WDR5 protein inhibitor (K_i= 0.008 μM). CS-VIP 8 hydrochloride induces conformational changes in the MLL1 complex, leading to the dissociation of MLL1 from the complex, inhibiting MLL1 histone methyltransferase activity and regulating HOX gene expression. CS-VIP 8 hydrochloride is promising for research of hematological diseases such as leukemia .

HY-P2254

H3K27(Me3) (15-34)	Histone Methyltransferase	Cancer
H3K27(Me3) (15-34), a histone peptide, is a repressive chromatin mark derived from human histone. Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of H3K27(Me) .

HY-19554

MM-401	WDR5 Apoptosis	Cancer
MM-401 is a MLL1 H3K4 methyltransferase inhibitor. MM-401 inhibits MLL1 activity (IC₅₀ = 0.32 μM) by blocking MLL1-WDR5 interaction. MM-401 can induce cell cycle arrest, apoptosis and differentiation. MM-401 can be used for the research of MLL leukemia .

HY-P2552

Histone H3 (1-21)	Peptides	Others
Histone H3 (1-21), derived from Histone H3 1-21 amino acids, is usually used as a substrate for methyltransferase (Histone 3 K4 and K9) and acetyltransferase (Histone 3 K9 and K14) assays .

HY-P10463

ssK36	Histone Methyltransferase	Cancer
ssK36 is a supersubstrate peptide of the histone methyltransferase (SET) domain protein 2 (SETD2), and ssK36 is designed for the SETD2 protein, a specific PKMT. ssK36 is responsible in human cells for adding methyl groups to the 36th lysine residue of histone H3 (H3K36) to form H3K36me3. ssK36 can be methylated by SETD2 at a rate more than 100 times faster than the natural substrate H3K36. ssK36 can be used to study the catalytic mechanism of PKMTs, especially substrate specificity and catalytic efficiency .

HY-P10948

CS-VIP 8	WDR5 Histone Methyltransferase	Cardiovascular Disease
CS-VIP 8 is a selective allosteric WDR5 protein inhibitor (K_i= 0.008 μM). CS-VIP 8 induces conformational changes in the MLL1 complex, leading to the dissociation of MLL1 from the complex, inhibiting MLL1 histone methyltransferase activity and regulating HOX gene expression. CS-VIP 8 is promising for research of hematological diseases such as leukemia .

HY-P10463A

ssK36 TFA	Histone Methyltransferase	Cancer
ssK36 TFA is a supersubstrate peptide of the histone methyltransferase (SET) domain protein 2 (SETD2) , and ssK36 TFA is designed for the SETD2 protein, a specific PKMT. ssK36 TFA is responsible in human cells for adding methyl groups to the 36th lysine residue of histone H3 (H3K36) to form H3K36me3. ssK36 TFA can be methylated by SETD2 at a rate more than 100 times faster than the natural substrate H3K36. ssK36 TFA can be used to study the catalytic mechanism of PKMTs, especially substrate specificity and catalytic efficiency .

HY-P2554

Histone H3 (1-25), amide	Peptides	Others
Histone H3 (1-25), amide is an N-terminal peptide fragment of histone H3. Histone H3 (1-25), amide can be used to identify the substrate for histone methyltransferases (HMTs). Histone H3 (1-25), amide, as a substrate for HMT G9a, shows more efficient than histone H3 (15-39) and full-length histone H3 .

HY-P2509

Histone H2A (1-20)	Peptides	Others
Histone H2A (1-20), a 35-residue a peptide of histone H2A, is a substrate for methyltransferase/demethylase enzymes .

HY-P2556

Histone H3 (21-44)	Biochemical Assay Reagents	Others
Histone H3 (21-44), derived from histone H3 21-44 amino acids, is usually used as a substrate (such as protein arginine methyltransferases) for methylation assays .

HY-P10570

[Nle20] H4 peptide (16−23)	Histone Methyltransferase	Cancer
[Nle20] H4 peptide (16−23) is a peptide with strong inhibitory activity against histone methyltransferase SETD8 (K_d=0.14 μM), which inhibits SETD8's methylation of histone H4 by competing with SETD8's substrate binding site. [Nle20] H4 peptide (16−23) can be used as a lead compound for anticancer therapy .

HY-P2252

H3K27(Me) (15-34)	Histone Methyltransferase	Cancer
H3K27(Me) (15-34), a histone peptide, is a repressive chromatin markderived from human histone. Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of H3K27(Me) .

HY-P5922

PTD2 Ac-Gly-Val-Nle-Arg-Ile-NH2	Histone Methyltransferase	Cancer
PTD2 (Ac-Gly-Val-Nle-Arg-Ile-NH2) is a potent, selective inhibitor of WHSC1. PTD2 exhibits micromolar affinity towards WHSC1 .

HY-P2253

H3K27(Me2) (15-34)	Histone Demethylase	Cancer
H3K27(Me2) (15-34), a histone peptide, is a repressive chromatin mark derived from human histone. Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of H3K27(Me) .

Cat. No.	상품명	Category	Target	Chemical Structure

HY-N2019

Chaetocin 5+ Cited Publications	Infection Alkaloids Microorganisms Classification of Application Fields Disease Research Fields Alkaloid Dimers Source Classification	Histone Methyltransferase Bacterial Antibiotic
Chaetocin is a specific inhibitor of the histone methyltransferase (HMT) SU(VAR)3-9 with an IC₅₀ of 0.6 μM for SU(VAR)3-9. It also inhibits thioredoxin reductase (TrxR) with an IC₅₀ of 4 μM.

HY-122936

Tanshindiol C	Terpenoids Labiatae Samanea saman (Jacq.) Merr. Diterpenoids Plants	Histone Methyltransferase Keap1-Nrf2 Sirtuin
Tanshindiol C is a S-adenosylmethionine-competitive EZH2 (Histone *Methyltransferase) inhibitor with an IC₅₀* of 0.55 μM for inhibiting the methyltransferase activity. Tanshindiol C is also an activator of both Nrf2 and Sirtuin 1 (Sirt1) in macrophages. Tanshindiol C possesses anti-cancer activity, and can be used for atherosclerosis research .

Species:	Human (11)
Tag:	His (4) Tag Free (2) Myc (1) GST (5)
Source:	Sf9 insect cells (4) E. coli (7)

Cat. No.	Compare	상품명	Species	Source	Image

HY-P790095

	CARM1 Protein, Human (His) Histone-arginine Methyltransferase CARM1; Coactivator-associated arginine Methyltransferase 1; Protein arginine N-Methyltransferase 4; CARM1; PRMT4	Human	E. coli
	CARM1 Protein, Human (His) is the recombinant human-derived CARM1, expressed by E. coli , with C-10*His labeled tag.

HY-P703071

	SETDB1 Protein, Human (sf9, GST) KMT1E; Histone-lysine N-Methyltransferase SETDB1; ERG-associated protein with SET domain (ESET); Histone H3-K9 Methyltransferase 4 (H3-K9-HMTase 4); Lysine N-Methyltransferase 1E; SET domain bifurcated 1; SETDB1; ESET	Human	Sf9 insect cells
	SETDB1 Protein, Human (sf9, GST) is the recombinant human-derived SETDB1, expressed by Sf9 insect cells , with GST labeled tag. ,

HY-P700258

	SMYD3 Protein, Human (His-Myc) Histone-lysine N-Methyltransferase SMYD3; ZMYND1; ZNFN3A1	Human	E. coli
	SMYD3 Protein, a histone methyltransferase, specifically induces di- and tri-methylation of H3K4, avoiding monomethylation, and methylates H4K5. Crucial in transcriptional activation within an RNA polymerase complex, SMYD3 also exhibits DNA-binding affinity for sequences containing 5'-CCCTCC-3' or 5'-GAGGGG-3'. Histone-lysine N-methyltransferase SMYD3 (SMYD3) Protein, Human (His-Myc) is the recombinant human-derived Histone-lysine N-methyltransferase SMYD3(SMYD3) protein, expressed by E. coli , with N-10*His, C-Myc labeled tag. Histone-lysine N-methyltransferase SMYD3 (SMYD3) Protein, Human (His-Myc), has molecular weight of 56.5 kDa.

HY-P76080

	SMYD3 Protein, Human (sf9, GST) Histone-lysine N-Methyltransferase SMYD3; ZMYND1; ZNFN3A1	Human	Sf9 insect cells
	SMYD3 Protein, a histone methyltransferase, specifically induces di- and tri-methylation of H3K4, avoiding monomethylation, and methylates H4K5. Crucial in transcriptional activation within an RNA polymerase complex, SMYD3 also exhibits DNA-binding affinity for sequences containing 5'-CCCTCC-3' or 5'-GAGGGG-3'. SMYD3 Protein, Human (sf9, GST) is the recombinant human-derived SMYD3 protein, expressed by Sf9 insect cells , with N-GST labeled tag.

HY-P77218

	SUV420H2 Protein, Human (His) Histone-lysine N-Methyltransferase KMT5C; KMT5C; PP7130	Human	E. coli
	SUV420H2 protein is a histone methyltransferase that methylates H4K20 to generate H4K20me3 and H4K20me2, which are critical for transcriptional regulation and genome integrity. SUV420H2 functions in pericentric heterochromatin, establishes constitutive heterochromatin, and interacts with RB1 family proteins. SUV420H2 Protein, Human (His) is the recombinant human-derived SUV420H2 protein, expressed by E. coli , with N-His labeled tag.

HY-P701589

	KMT2D Protein, Human KMT2D; Histone-lysine N-Methyltransferase 2D; Lysine N-Methyltransferase 2D; ALL1-related protein; Myeloid/lymphoid or mixed-lineage leukemia protein 2	Human	E. coli
	KMT2D Protein, a histone methyltransferase, methylates histone H3 'Lys-4' (H3K4), predominantly establishing H3K4me1 marks at active chromatin sites. Integral to chromatin remodeling, it functions as a coactivator for the estrogen receptor, recruited by ESR1, activating transcription. KMT2D's role in depositing specific histone marks at genomic locations underscores its crucial involvement in modulating chromatin structure and gene expression. KMT2D Protein, Human is the recombinant human-derived KMT2D protein, expressed by E. coli , with tag free.

HY-P701590

	KMT2D Protein, Human (GST) KMT2D; Histone-lysine N-Methyltransferase 2D; Lysine N-Methyltransferase 2D; ALL1-related protein; Myeloid/lymphoid or mixed-lineage leukemia protein 2	Human	E. coli
	KMT2D Protein, a histone methyltransferase, methylates histone H3 'Lys-4' (H3K4), predominantly establishing H3K4me1 marks at active chromatin sites. Integral to chromatin remodeling, it functions as a coactivator for the estrogen receptor, recruited by ESR1, activating transcription. KMT2D's role in depositing specific histone marks at genomic locations underscores its crucial involvement in modulating chromatin structure and gene expression. KMT2D Protein, Human (GST) is the recombinant human-derived KMT2D protein, expressed by E. coli , with N-GST labeled tag.

HY-P75283

	DOT1L Protein, Human Histone H3-K79 Methyltransferase; H3-K79-HMTase; DOT1L; KIAA1814; KMT4	Human	E. coli
	The DOT1L protein, a histone methyltransferase, methylates lysine-79 of histone H3. It shows high activity against nucleosomes but not free core histones. It is broadly expressed, particularly in tissues like the testis, bone marrow, and 22 other tissues. DOT1L Protein, Human is the recombinant human-derived DOT1L protein, expressed by E. coli , with tag free.

HY-P704190

	DOT1L Protein, Human (Active, sf9, GST) Histone H3-K79 Methyltransferase; H3-K79-HMTase; DOT1L; KIAA1814; KMT4	Human	Sf9 insect cells
	DOT1L Protein, Human (Active, sf9, GST) is the recombinant human-derived DOT1L protein, expressed by Sf9 insect cells, with N-GST tag.

HY-P76062

	SETD7 Protein, Human (His) Histone-lysine N-Methyltransferase SETD7; H3-K4-HMTase SETD7; SET7/9; KIAA1717; KMT7; SET7; SET9	Human	E. coli
	The SETD7 protein is a histone methyltransferase that specifically monomethylates H3K4, a mark associated with transcriptional activation. Its role in gene activation extends to the collagenase and insulin genes, specifically at the insulin promoter when IPF1/PDX-1 is recruited. SETD7 Protein, Human (His) is the recombinant human-derived SETD7 protein, expressed by E. coli , with N-His labeled tag.

HY-P705547

	SETD7 Protein, Human (sf9, GST) Histone-lysine N-Methyltransferase SETD7; H3-K4-HMTase SETD7; SET7/9; KIAA1717; KMT7; SET7; SET9	Human	Sf9 insect cells
	The SETD7 protein is a histone methyltransferase that specifically monomethylates H3K4, a mark associated with transcriptional activation. Its role in gene activation extends to the collagenase and insulin genes, specifically at the insulin promoter when IPF1/PDX-1 is recruited. SETD7 Protein, Human (sf9, GST) is the recombinant human-derived SETD7 protein, expressed by Sf9 insect cells , with N-GST labeled tag.

Compare Products


Products	해외재고보유 - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 해외재고보유 - + 장바구니에 담기 견적 받기

Host:	Mouse (11) Rabbit (8)
Reactivity:	Human (18) Rat (8) Mouse (12) Monkey (1) Rabbit (1) Dog (1)
Application:	IHC-P (10) ICC/IF (3) IF-Tissue (1) IP (3) WB (17) FC (3) ELISA (4)
Isotype:	IgG (8)
Conjugation:	Non-conjugated (19)
Clonality:	Monoclonal (17) Recombinant (7)
Modification:	Unmodified (17)

Cat. No.	Compare	상품명	Application	Reactivity	Image

HY-P85492

	CARM1 Antibody (YA5184) carm1; CARM1_HUMAN; Coactivator associated arginine Methyltransferase 1; Coactivator-associated arginine Methyltransferase 1; Histone arginine Methyltransferase CARM 1; Histone arginine Methyltransferase CARM1; Histone-arginine Methyltransferase CARM1; PRMT 4; PRMT4; Protein arginine Methyltransferase; Protein arginine N Methyltransferase 4; Protein arginine N-Methyltransferase 4.	WB, IP	Human, Mouse
	CARM1 Antibody (YA5184) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CARM1.

HY-P85335

	CARM1 Antibody (YA5027) CARM1; PRMT4; Histone-arginine Methyltransferase CARM1; Coactivator-associated arginine Methyltransferase 1; Protein arginine N-Methyltransferase 4	WB, IHC-P, IP	Human, Mouse, Rat
	CARM1 Antibody (YA5027) is a Rabbit-derived and non-conjugated recombinant monoclonal antibody, targeting to CARM1.

HY-P85460

	PRMT6 Antibody (YA5152) PRMT6; HRMT1L6; Protein arginine N-Methyltransferase 6; Heterogeneous nuclear ribonucleoprotein Methyltransferase-like protein 6; Histone-arginine N-Methyltransferase PRMT6	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	PRMT6 Antibody (YA5152) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PRMT6.

HY-P85132

	EHMT1 Antibody (YA4824) EHMT1; EUHMTASE1; GLP; KIAA1876; KMT1D; Histone-lysine N-Methyltransferase EHMT1; Euchromatic Histone-lysine N-Methyltransferase 1; Eu-HMTase1; G9a-like protein 1; GLP; GLP1; Histone H3-K9 Methyltransferase 5; H3-K9-HMTase 5; Lysine N-methy	WB, ELISA	Human
	EHMT1 Antibody (YA4824) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to EHMT1.

HY-P83151

	SETD7 Antibody (YA2896) Histone H3-K4 Methyltransferase SETD7; Lysine N-Methyltransferase 7; SET domain-containing protein 7; SET7; SET9	WB, IP	Human, Mouse, Rat
	SETD7 Antibody (YA2896) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SETD7.

HY-P85154

	SETDB1/ESET Antibody (YA4846) SETDB1; KIAA0067; KMT1E; Histone-lysine N-Methyltransferase SETDB1; ERG-associated protein with SET domain; ESET; Histone H3-K9 Methyltransferase 4; H3-K9-HMTase 4; Lysine N-Methyltransferase 1E; SET domain bifurcated 1	WB, ICC/IF, ELISA	Human, Mouse, Monkey
	SETDB1/ESET Antibody (YA4846) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to SETDB1/ESET.

HY-P85496

	PRMT6 Antibody (YA5188) ANM6_HUMAN; Chromobox protein homolog 7; FLJ10559; FLJ51477; Heterogeneous nuclear ribonucleoprotein Methyltransferase like protein 6; Heterogeneous nuclear ribonucleoprotein Methyltransferase-like protein 6; Histone-arginine N-Methyltransferase PRMT6; HMT1 hnRNP Methyltransferase like 6.; HRMT1L6; OTTHUMP00000012633; PRMT 6; prmt6; Protein arginine Methyltransferase 6; Protein arginine N Methyltransferase 6; Protein arginine N-Methyltransferase 6.	WB, IHC-P, ICC/IF	Human
	PRMT6 Antibody (YA5188) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PRMT6.

HY-P87161

	hSET1/SET1 Antibody (YA6854) Histone-lysine N-Methyltransferase SETD1A antibody; hSET1A antibody; KMT2F antibody; Lysine N Methyltransferase 2F antibody; Lysine N-Methyltransferase 2F antibody; SET domain containing 1A antibody; SET domain containing protein 1A antibody; SET domain-containing protein 1A antibody; SET1 antibody; Set1 Ash2 Histone Methyltransferase complex subunit SET1 antibody; Histone-lysine N-Methyltransferase SETD1A antibody; hSET1A antibody; KMT2F antibody; Lysine N Methyltransferase 2F antibody; Lysine N-Methyltransferase 2F antibody; SET domain containing 1A antibody; SET domain containing protein 1A antibody; SET domain-containing protein 1A antibody; SET1 antibody; Set1 Ash2 Histone Methyltransferase complex subunit SET1 antibody; Set1/Ash2 Histone Methyltransferase complex subunit SET1 antibody; SET1A antibody; SET1A_HUMAN antibody; SETD1A antibody;	WB, FC	Human
	hSET1/SET1 Antibody (YA6854) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to hSET1/SET1.

HY-P85459

	PRMT1 Antibody (YA5151) PRMT1; HMT2; HRMT1L2; IR1B4; Protein arginine N-Methyltransferase 1; Histone-arginine N-Methyltransferase PRMT1; Interferon receptor 1-bound protein 4	WB	Human, Mouse, Rat, Dog, Rabbit
	PRMT1 Antibody (YA5151) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PRMT1.

HY-P810412

	NSD3 Antibody (YA9727) DKFZp667H044, FLJ20353, Histone lysine N Methyltransferase NSD3, Histone-lysine N-Methyltransferase NSD3, MGC126766, MGC142029, NSD 3, NSD3_HUMAN, Nuclear set domain containing 3, Nuclear SET domain containing protein 3	WB, FC, IHC-P	Human, Mouse, Rat
	NSD3 Antibody (YA9727) is a Rabbit-derived and non-conjugated IgG Recombinant,Monoclonal antibody, targeting to NSD3.

HY-P81657

	KMT4 Antibody (YA1402) DOT 1; DOT1L; KMT4; Histone Methyltransferase DOT1L; H3 lysine-79 specific	WB, IHC-P	Human, Mouse
	KMT4 Antibody (YA1402) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to KMT4.

HY-P81657A

	KMT4 Antibody (YA1402)(PBS only) DOT 1; DOT1L; KMT4; Histone Methyltransferase DOT1L; H3 lysine-79 specific	WB, IHC-P	Human, Mouse
	KMT4 Antibody (YA1402) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to KMT4.

HY-P85491

	SMYD2 Antibody Histone Methyltransferase SMYD2; HSKM B; HSKM-B; HSKMB; KMT3C; Lysine N-Methyltransferase 3C; MGC119305; N lysine Methyltransferase SMYD2; N-lysine Methyltransferase SMYD2; SET and MYND domain containing 2; SET and MYND domain containing protein 2; SET and MYND domain-containing protein 2; Smyd2; SMYD2_HUMAN; Zinc finger MYND domain containing 14; ZMYND14.	WB, IHC-P, IF-Tissue	Human, Mouse
	SMYD2 Antibody is a Rabbit-derived and non-conjugated polyclonal antibody, targeting to SMYD2.

HY-P83329

	NSD3 Antibody (YA3074) Wolf Hirschhorn syndrome candidate 1 like 1; WHSC1L1; NSD3; pp14328; Histone-lysine N-Methyltransferase NSD3; Protein whistle	WB, FC	Human, Mouse, Rat
	NSD3 Antibody (YA3074) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to NSD3.

HY-P85279

	KMT2A Antibody (YA4971) MLL; ALL1; CXXC7; HRX; HTRX; KMT2A; MLL1; TRX1; Histone-lysine N-Methyltransferase MLL; ALL-1; CXXC-type zinc finger protein 7; Lysine N-Methyltransferase 2A; KMT2A; Trithorax-like protein; Zinc finger protein HRX	IHC-P, ELISA	Human
	KMT2A Antibody (YA4971) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to KMT2A.

HY-P85279A

	KMT2A Antibody (YA4971)(PBS only) MLL; ALL1; CXXC7; HRX; HTRX; KMT2A; MLL1; TRX1; Histone-lysine N-Methyltransferase MLL; ALL-1; CXXC-type zinc finger protein 7; Lysine N-Methyltransferase 2A; KMT2A; Trithorax-like protein; Zinc finger protein HRX	IHC-P, ELISA	Human
	KMT2A Antibody (YA4971) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to KMT2A.

HY-P85501

	SMYD1 Antibody (YA5193) BOP; CD8 beta opposite; CD8b opposite; Histone lysine N Methyltransferase SMYD1; KMT3D; SET and MYND domain-containing protein 1; SMYD1; SMYD1_HUMAN; Zinc finger MYND domain containing 18; ZMYND18; ZMYND22; zinc finger, MYND domain containing 18.	WB	Rat
	SMYD1 Antibody (YA5193) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to SMYD1.

HY-P85445

	NSD1 Antibody (YA5137) NSD1; ARA267; KMT3B; Histone-lysine N-Methyltransferase; H3 lysine-36 and H4 lysine-20 specific; Androgen receptor coactivator 267 kDa protein; Androgen receptor-associated protein of 267 kDa; H3-K36-HMTase; H4-K20-HMTase; Lysine N-methyltr	WB	Human
	NSD1 Antibody (YA5137) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to NSD1.

HY-P87049

	REIIBP/NSD2 Antibody (YA6742) FLJ23286 antibody; IL5 promoter REII region binding protein antibody; KIAA1090 antibody; MGC176638 antibody; MMSET antibody; MMSET type II antibody; Multiple myeloma SET domain containing protein type III antibody; Multiple myeloma SET domain protein antibody; Multiple myeloma SET domain-containing protein antibody; NSD 2 antibody; FLJ23286 antibody; IL5 promoter REII region binding protein antibody; KIAA1090 antibody; MGC176638 antibody; MMSET antibody; MMSET type II antibody; Multiple myeloma SET domain containing protein type III antibody; Multiple myeloma SET domain protein antibody; Multiple myeloma SET domain-containing protein antibody; NSD 2 antibody; NSD2 antibody; NSD2_HUMAN antibody; Nuclear receptor binding SET domain protein 2 antibody; Nuclear SET domain-containing protein 2 antibody; Probable Histone-lysine N-Methyltransferase NSD2 antibody; Protein trithorax-5 antibody; REIIBP antibody; Trithorax/ash1 related protein 5 antibody; TRX5 antibody; TRX5 protein antibody; WHS antibody; Whsc1 antibody; Wolf Hirschhorn syndrome candidate 1 antibody; Wolf Hirschhorn syndrome candidate 1 protein antibody; Wolf-Hirschhorn syndrome candidate 1 protein antibody;	WB, IHC-P	Human, Mouse, Rat
	REIIBP/NSD2 Antibody (YA6742) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to REIIBP/NSD2.

Compare Products


Products	해외재고보유 - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 해외재고보유 - + 장바구니에 담기 견적 받기

Cat. No.	상품명		Classification

HY-181849

MS2928		Alkynes
MS2928 is a selective SETD8 inhibitor with an IC₅₀ of 0.14 μM against SETD8 methyltransferase activity. MS2928 reduces cellular H4K20_me1 levels and inhibits proliferation of SETD8-overexpressing multiple myeloma cells. MS2928 inhibits tumor growth in xenograft mouse models of SETD8-overexpressing multiple myeloma. MS2928 can be used for the study of SETD8 biological functions and multiple myeloma .

Targets Recommended: Histone Methyltransferase Histone Demethylase HDAC Amine N-methyltransferase Histone Acetyltransferase METTL3 COMT ICMT RNA MTase DNA Methyltransferase

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-12186G

3-Deazaneplanocin A hydrochloride DZNep hydrochloride; NSC 617989 hydrochloride; 3-Deazaneplanocin hydrochloride	Histone Methyltransferase Orthopoxvirus	Infection Cancer
3-Deazaneplanocin A (DZNep) hydrochloride (GMP) is 3-Deazaneplanocin A hydrochloride (HY-12186) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. 3-Deazaneplanocin A hydrochloride is a potent histone methyltransferase EZH2 inhibitor .

HY-13689G

Go 6983	PKC Histone Methyltransferase DNA Methyltransferase DNA/RNA Synthesis	Inflammation/Immunology
Go 6983 GMP is Go 6983 (HY-13689) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Go 6983 is a dual inhibitor targeting Suv39h1/2 (KMT1A/KMT1B) and PKC, as well as a transcriptional activator capable of inducing DNA hypomethylation. Go 6983 stimulates the transcription of Prdm14 by reducing Suv39h1/2 protein levels, decreasing histone modifications in the Prdm14 promoter region, and increasing the recruitment of RNA polymerase II. Go 6983 induces genome-wide DNA hypomethylation by inhibiting de novo methyltransferase expression and increasing Tet1/Tet2 levels, thereby promoting self-renewal and pluripotency maintenance of stem cells. Meanwhile, Go 6983 can block PKC-mediated signaling pathways to reduce the expression of EMT-related genes and eliminate the upregulation of antioxidant genes downstream of NRF2. Go 6983 is mainly used in mechanism studies related to myocardial ischemia/reperfusion injury .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

Histone Methyltransferase

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Antibodies

Click Chemistry

GMP Molecules

Natural
Products